• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

自互补型 AAV5 载体促进正常小鼠光感受器和视网膜色素上皮细胞中转基因的更快表达。

Self-complementary AAV5 vector facilitates quicker transgene expression in photoreceptor and retinal pigment epithelial cells of normal mouse.

机构信息

Eye Hospital, School of Ophthalmology & Optometry, Wenzhou Medical College, Wenzhou 325027, China.

出版信息

Exp Eye Res. 2010 May;90(5):546-54. doi: 10.1016/j.exer.2010.01.011. Epub 2010 Feb 4.

DOI:10.1016/j.exer.2010.01.011
PMID:20138034
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2854182/
Abstract

To clarify whether transduction efficiency and cell type specificity of self-complementary (sc) AAV5 vectors are similar to those of standard, single-stranded AAV5 vectors in normal retina, one micro liter of scAAV5-smCBA-GFP vector (1 x 10(12) genome-containing particles/ml) and AAV5-smCBA-GFP vector (1 x 10(12) genome-containing particles/ml) were subretinally or intravitreally (in both cases through the cornea) injected into the right and left eyes of adult C57BL/6J mice, respectively. On post-injection day (PID) 1, 2, 5, 7, 10, 14, 21, 28 and 35, eyes were enucleated; retinal pigment epithelium (RPE) wholemounts, neuroretinal wholemounts and eyecup sections were prepared to evaluate green fluorescent protein (GFP) expression by fluorescent microscopy. GFP expression following trans-cornea subretinal injection of scAAV5-smCBA-GFP vector was first detected in RPE wholemounts around PID 1 and in neuroretinal wholemounts between PID 2 and 5; GFP expression peaked and stabilized between PID 10-14 in RPE wholemounts and between P14 and P21 in neuroretinal wholemounts with strong, homogeneous green fluorescence covering the entire wholemounts. The frozen sections supported the following findings from the wholemounts: GFP expression appeared first in RPE around PID 1-2 and soon spread to photoreceptors (PR) cells; by PID 7, moderate GFP expression was found mainly in PR and RPE layers; between PID 14 and 21, strong and homogenous GFP expression was observed in RPE and PR cells. GFP expression following subretinal injection of AAV5-smCBA-GFP was first detected in RPE wholemounts around PID 5-7 and in neuroretinal wholemounts around PID 7-10; ssAAV5-mediated GFP expression peaked at PID 21 in RPE wholemounts and around PID 28 in neuroretinal wholemounts; sections from AAV5 treated eyes also supported findings obtained from wholemounts: GFP expression was first detected in RPE and then spread to the PR cells. Peak GFP expression in RPE mediated by scAAV5 was similar to that mediated by AAV5. However, peak GFP expression mediated by scAAV5 in PR cells was stronger than that mediated by AAV5. No GFP fluorescence was detected in any retinal cells (RPE wholemounts, neuroretinal wholemounts and retinal sections) after trans-cornea intravitreal delivery of either scAAV5-GFP or AAV5-GFP. Neither scAAV5 nor AAV5 can transduce retinal cells following trans-cornea intravitreal injection. The scAAV5 vector used in this study directs an earlier onset of transgene expression than the matched AAV5 vector, and has stronger transgene expression in PR cells following subretinal injection. Our data confirm the previous reports that scAAV vectors have an earlier onset than the standard, single strand AAV vectors (Natkunarajah et al., 2008; Yokoi et al., 2007). scAAV5 vectors may be more useful than standard, single-stranded AAV vector when addressing certain RPE and/or PR cell-related models of retinal dystrophy, particularly for mouse models of human retinitis pigmentosa that require rapid and robust transgene expression to prevent early degeneration in PR cells.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/474b/2854182/c1c874ab6df9/nihms177507f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/474b/2854182/e472a940e55a/nihms177507f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/474b/2854182/c836b98ddb36/nihms177507f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/474b/2854182/9ae1bef28a8b/nihms177507f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/474b/2854182/1b8e4f12967c/nihms177507f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/474b/2854182/c1c874ab6df9/nihms177507f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/474b/2854182/e472a940e55a/nihms177507f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/474b/2854182/c836b98ddb36/nihms177507f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/474b/2854182/9ae1bef28a8b/nihms177507f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/474b/2854182/1b8e4f12967c/nihms177507f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/474b/2854182/c1c874ab6df9/nihms177507f5.jpg
摘要

为了明确自互补(sc)AAV5 载体的转导效率和细胞类型特异性是否与标准的单链 AAV5 载体在正常视网膜中相似,我们将 1 微升 scAAV5-smCBA-GFP 载体(1×10(12)基因组含量颗粒/ml)和 AAV5-smCBA-GFP 载体(1×10(12)基因组含量颗粒/ml)通过巩膜下或玻璃体内(两种情况下均通过角膜)分别注射到成年 C57BL/6J 小鼠的右眼和左眼。在注射后第 1、2、5、7、10、14、21、28 和 35 天,取出眼球;制备视网膜色素上皮(RPE)全层、神经视网膜全层和眼杯切片,通过荧光显微镜评估绿色荧光蛋白(GFP)的表达。在 scAAV5-smCBA-GFP 载体经角膜巩膜下注射后,首次在 RPE 全层中观察到 GFP 表达,时间约为注射后第 1 天,在神经视网膜全层中观察到 GFP 表达的时间约为第 2-5 天;在 RPE 全层中,GFP 表达在注射后第 10-14 天达到峰值并稳定下来,在神经视网膜全层中,GFP 表达在第 14 天和第 21 天达到峰值,具有强烈、均匀的绿色荧光覆盖整个全层。冷冻切片支持全层的以下发现:GFP 表达首先出现在 RPE 周围的第 1-2 天,并且很快传播到感光细胞(PR)细胞;在第 7 天,主要在 PR 和 RPE 层中发现中度 GFP 表达;在第 14 天至第 21 天之间,在 RPE 和 PR 细胞中观察到强烈和均匀的 GFP 表达。在 RPE 全层中,通过巩膜下注射 AAV5-smCBA-GFP 后首次观察到 GFP 表达,在神经视网膜全层中,通过巩膜下注射 AAV5-smCBA-GFP 后首次观察到 GFP 表达,时间约为第 5-7 天;ssAAV5 介导的 GFP 表达在 RPE 全层中于第 21 天达到峰值,在神经视网膜全层中于第 28 天达到峰值;来自 AAV5 处理的眼的切片也支持从全层获得的发现:GFP 表达首先在 RPE 中检测到,然后传播到 PR 细胞。scAAV5 介导的 GFP 表达在 RPE 中的峰值与 AAV5 介导的 GFP 表达相似。然而,scAAV5 介导的 GFP 表达在 PR 细胞中的峰值强于 AAV5 介导的 GFP 表达。在任何视网膜细胞(RPE 全层、神经视网膜全层和视网膜切片)中均未检测到 GFP 荧光,在通过角膜玻璃体内注射 scAAV5-GFP 或 AAV5-GFP 后。scAAV5 或 AAV5 均不能在经角膜玻璃体内注射后转导视网膜细胞。本研究中使用的 scAAV5 载体比匹配的 AAV5 载体更早开始转基因表达,并且在巩膜下注射后在 PR 细胞中有更强的转基因表达。我们的数据证实了之前的报道,即 scAAV 载体比标准的单链 AAV 载体更早开始(Natkunarajah 等人,2008 年;Yokoi 等人,2007 年)。在某些与 RPE 和/或 PR 细胞相关的视网膜变性模型中,scAAV5 载体可能比标准的单链 AAV 载体更有用,特别是对于需要快速和强大的转基因表达以防止 PR 细胞早期退化的人类色素性视网膜炎的小鼠模型。

相似文献

1
Self-complementary AAV5 vector facilitates quicker transgene expression in photoreceptor and retinal pigment epithelial cells of normal mouse.自互补型 AAV5 载体促进正常小鼠光感受器和视网膜色素上皮细胞中转基因的更快表达。
Exp Eye Res. 2010 May;90(5):546-54. doi: 10.1016/j.exer.2010.01.011. Epub 2010 Feb 4.
2
Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye.视网膜下注射AAV5载体后的基因治疗不受对侧眼先前玻璃体内注射AAV5载体的影响。
Mol Vis. 2009;15:267-75. Epub 2009 Feb 6.
3
Efficiency of lentiviral transduction during development in normal and rd mice.正常小鼠和视网膜色素变性(rd)小鼠发育过程中慢病毒转导的效率。
Mol Vis. 2006 Jul 11;12:756-67.
4
Ocular gene transfer with self-complementary AAV vectors.使用自我互补腺相关病毒载体进行眼部基因转移。
Invest Ophthalmol Vis Sci. 2007 Jul;48(7):3324-8. doi: 10.1167/iovs.06-1306.
5
Quantifying transduction efficiencies of unmodified and tyrosine capsid mutant AAV vectors in vitro using two ocular cell lines.使用两种眼细胞系在体外定量未修饰的和酪氨酸衣壳突变型腺相关病毒(AAV)载体的转导效率。
Mol Vis. 2011 Apr 29;17:1090-102.
6
Human blue-opsin promoter preferentially targets reporter gene expression to rat s-cone photoreceptors.人类蓝色视蛋白启动子优先将报告基因的表达靶向大鼠S-视锥光感受器。
Invest Ophthalmol Vis Sci. 2006 Aug;47(8):3505-13. doi: 10.1167/iovs.05-1670.
7
Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors.通过使用新型、衣壳突变的 AAV 载体经玻璃体腔递送来靶向感光细胞。
PLoS One. 2013 Apr 26;8(4):e62097. doi: 10.1371/journal.pone.0062097. Print 2013.
8
Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size.腺相关病毒介导的小鼠视网膜病毒转导:病毒衣壳和基因组大小的影响
J Virol. 2002 Aug;76(15):7651-60. doi: 10.1128/jvi.76.15.7651-7660.2002.
9
Evaluation of lateral spread of transgene expression following subretinal AAV-mediated gene delivery in dogs.评价犬视网膜下腔注射 AAV 介导的基因转导后转基因表达的侧向扩散。
PLoS One. 2013;8(4):e60218. doi: 10.1371/journal.pone.0060218. Epub 2013 Apr 3.
10
[Expression pattern of different serotypes of adeno-associated viral vectors in mouse retina].[不同血清型腺相关病毒载体在小鼠视网膜中的表达模式]
Beijing Da Xue Xue Bao Yi Xue Ban. 2020 Oct 18;52(5):845-850. doi: 10.19723/j.issn.1671-167X.2020.05.008.

引用本文的文献

1
AAV-IKV mediated expression of decorin inhibits EMT and fibrosis in a murine model of Glaucoma and AAV-IKV transduction in Non-Human Primates.腺相关病毒-IKV介导的核心蛋白聚糖表达可抑制青光眼小鼠模型中的上皮-间质转化和纤维化以及非人灵长类动物中的腺相关病毒-IKV转导。
Sci Rep. 2025 Mar 7;15(1):8051. doi: 10.1038/s41598-025-92273-5.
2
Effects of chemogenetic virus injection and clozapine administration in spinal cord injury.化学遗传病毒注射与氯氮平给药对脊髓损伤的影响。
Neurotherapeutics. 2025 Mar;22(2):e00547. doi: 10.1016/j.neurot.2025.e00547. Epub 2025 Feb 14.
3
Evaluation of neuroretina following i.v. or intra-CSF AAV9 gene replacement in mice with MPS IIIA, a childhood dementia.

本文引用的文献

1
Vision 1 year after gene therapy for Leber's congenital amaurosis.莱伯先天性黑矇症基因治疗1年后的视力情况。
N Engl J Med. 2009 Aug 13;361(7):725-7. doi: 10.1056/NEJMc0903652.
2
Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year.用于莱伯先天性黑蒙的人RPE65基因疗法:早期视力改善的持续性及1年安全性
Hum Gene Ther. 2009 Sep;20(9):999-1004. doi: 10.1089/hum.2009.086.
3
Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye.
MPS IIIA 型幼年痴呆症小鼠静脉内或鞘内 AAV9 基因替代治疗后神经视网膜评估。
CNS Neurosci Ther. 2024 Aug;30(8):e14919. doi: 10.1111/cns.14919.
4
Intravitreal injection of new adeno-associated viral vector: Enhancing retinoschisin 1 gene transduction in a mouse model of X-linked retinoschisis.玻璃体内注射新型腺相关病毒载体:增强X连锁视网膜劈裂症小鼠模型中视网膜劈裂蛋白1基因的转导
Biochem Biophys Rep. 2024 Feb 6;37:101646. doi: 10.1016/j.bbrep.2024.101646. eCollection 2024 Mar.
5
Preclinical dose response study shows NR2E3 can attenuate retinal degeneration in the retinitis pigmentosa mouse model Rho.临床前剂量反应研究表明,NR2E3 可减轻 Rho 型色素性视网膜炎小鼠模型的视网膜变性。
Gene Ther. 2024 May;31(5-6):255-262. doi: 10.1038/s41434-024-00440-6. Epub 2024 Jan 26.
6
Role of Adiponectin Peptide I (APNp1) in Age-Related Macular Degeneration.脂联素肽 I(APNp1)在年龄相关性黄斑变性中的作用。
Biomolecules. 2022 Sep 3;12(9):1232. doi: 10.3390/biom12091232.
7
Overexpression of Substance P in pig airways increases MUC5AC through an NF-kβ pathway.猪气道中 P 物质的过表达通过 NF-κβ 通路增加 MUC5AC。
Physiol Rep. 2021 Feb;9(3):e14749. doi: 10.14814/phy2.14749.
8
Novel insights into gene therapy in the cornea.角膜基因治疗的新见解。
Exp Eye Res. 2021 Jan;202:108361. doi: 10.1016/j.exer.2020.108361. Epub 2020 Nov 16.
9
Gene Therapy Preserves Retinal Structure and Function in a Mouse Model of -Associated Retinal Degeneration.基因疗法在与[疾病名称]相关的视网膜变性小鼠模型中保留视网膜结构和功能。 (你提供的原文中“-Associated”处应该有具体疾病名称缺失,我按格式翻译了完整句子结构,你可补充完整准确内容)
Mol Ther Methods Clin Dev. 2020 Jul 9;18:582-594. doi: 10.1016/j.omtm.2020.07.003. eCollection 2020 Sep 11.
10
Molecular Therapies for Inherited Retinal Diseases-Current Standing, Opportunities and Challenges.遗传性视网膜疾病的分子治疗——现状、机遇与挑战。
Genes (Basel). 2019 Aug 28;10(9):654. doi: 10.3390/genes10090654.
视网膜下注射AAV5载体后的基因治疗不受对侧眼先前玻璃体内注射AAV5载体的影响。
Mol Vis. 2009;15:267-75. Epub 2009 Feb 6.
4
High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors.酪氨酸突变型腺相关病毒血清型载体对小鼠视网膜的高效转导
Mol Ther. 2009 Mar;17(3):463-71. doi: 10.1038/mt.2008.269. Epub 2008 Dec 16.
5
Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential.AAV2载体眼内给药途径决定体液免疫反应和治疗潜力。
Mol Vis. 2008 Sep 24;14:1760-9.
6
Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics.针对RPE65异构酶缺乏症的人类基因疗法可激活视觉的视黄醛循环,但视杆动力学缓慢。
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15112-7. doi: 10.1073/pnas.0807027105. Epub 2008 Sep 22.
7
AAV-mediated gene therapy for retinal degeneration in the rd10 mouse containing a recessive PDEbeta mutation.腺相关病毒介导的基因疗法用于治疗携带隐性磷酸二酯酶β突变的rd10小鼠的视网膜变性。
Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4278-83. doi: 10.1167/iovs.07-1622. Epub 2008 Jun 27.
8
Effect of gene therapy on visual function in Leber's congenital amaurosis.基因治疗对莱伯先天性黑蒙视觉功能的影响。
N Engl J Med. 2008 May 22;358(21):2231-9. doi: 10.1056/NEJMoa0802268. Epub 2008 Apr 27.
9
Safety and efficacy of gene transfer for Leber's congenital amaurosis.基因转移治疗莱伯先天性黑蒙的安全性和有效性。
N Engl J Med. 2008 May 22;358(21):2240-8. doi: 10.1056/NEJMoa0802315. Epub 2008 Apr 27.
10
Assessment of ocular transduction using single-stranded and self-complementary recombinant adeno-associated virus serotype 2/8.使用单链和自互补重组腺相关病毒血清型2/8评估眼部转导。
Gene Ther. 2008 Mar;15(6):463-7. doi: 10.1038/sj.gt.3303074. Epub 2007 Nov 15.